Recent Finacing
Recent Raise
Armatus Bio develops vectorized RNAi gene therapies using AAV capsids (e.g., AAV‑SLB101) for genetically driven neuromuscular diseases, including ARM‑201 targeting DUX4 in FSHD and ARM‑101 for CMT1A.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Armatus Bio.
